Cop ISPLAD - Salute per tutti

Evaluation of the efficacy of a dietary supplement containing polyunsaturated fatty acids (PUFAs) and vitamins in the management of dermatitis
copper (Table 2). It is a powder that can be swallowed
with water, milk, fruit juice or yogurt.
We suggested one packet/day, corresponding to
twenty grams ƒof product, for 56 patients
(93.33%), over a period of two months. Only
four patients (6.66%) with a low body mass
area (BMA < 17) used a reduced dosage of half
a packet/day.
Table 3.
Clinical score system.
Score Clinical estimation
1 Worsening
2 No improvement
3 Slight or modest improvement
4 Marked improvement
Table 4.
Results.
Clinical score Group A Group B
1 6 (10%) 2 (3.33 %)
2 7 (11.66%) 20
3 16 (20%) 22
4 23 (38.33%) 12
Lost to follow-up 8 4
Table 5.
Group A: results after one or more cycle of therapy with ADskin.
Clinical score One cycle More than one cycle
of therapy of therapy
1 6 (10%) 2 (3.33%)
2 7 (11.66%) 20
3 16 (20%) 22
4 23 (38.33%) 12
Lost to follow-up 8 4
Group A Group A after Rx Group A after follow up
VAS 68 ± 18 46 ± 12 52 ± 20
Scorad 38 ± 18 18 ± 8 29 ± 22
Group B Group B after Rx
VAS 69 ± 13 56 ± 17
Scorad 37 ± 12 19 ± 14
On the other hand, the GB patients used the
same traditional eczema treatments, as for GA.
Patients were subjected to clinical visits every 3
weeks when they also showed a VAS score for
the seriousness of their pruritus filled at home.
At these moments patients were evaluated
using a clinical scoring system (Table 3) and
calculating SCORAD values.
r esults
We considered the effects of the dietary
intake of PUFAs and vitamins on the severity
of dermatitis, on pruritus.
52 GA patients out of 60 completed the 2
months therapy with this diet supplementation
in addition to conventional eczema therapy.
Eight patients decided to interrupt the therapy
for personal problems (13.33%) 52 patients
were followed up for one other month after
withdrawl of this preparation.
39 patients out of 52 of the GA (65%) using the
clinical scoring system noticed a reduction in
clinical symptoms especially pruritus In particular,
after one cycle of treatment, 23 patients
referred a marked improvement in their condition
(score 4) and 8 patients declared a mild or
modest improvement (score 3). Moreover, from
this group of patients 14 (23.33%) declared an
improvement in pruritus as well as a reduction
in the skin inflammation. On the contrary, 7
patients (21.66%) declared that there were no
changes and 6 that they had noticed a worsening
of their dermatitis. We observed a progressive
improvement in the treated group as relieved
by Scorad and by VAS versus the traditionally
treated group but only after two months
of treatment we obtain a statistically significant
improvement. (p < 0,05 for both parameters).
During the follow up patients symptoms behave
as the control groups. 14 patients that obtained
the better results performed other cycles of
therapy with a progressive clear improvement
of pruritus in eight of them (Table 5). Three of
these patients kept ADskin as their unique therapy
now withdrawning antihistamines and
other topical treatments but emollients. No
side effects were recorded by these patients
(Table 4).
In GB 4 patients decided to interrupt therapy
and in the remaining group of 56 we observed
an improvement in pruritus in 34 patients; 12
patients in particular declared a high reduction
Journal of Plastic Dermatology 2010; 6, 2 123